http://dx.doi.org/10.18081/2333-5106/019-2/138-150
Received January 09, 2019; Accepted May 23, 2019; Published June 22, 2019
Najah R. Hadi; Fadhil G. Al-Amran; Maitham G Yousif; Suhaad T. Zamil 1
Abstract
Myocardial ischemia–reperfusion (I-R) represents a clinically relevant problem associated with thrombolysis, angioplasty and coronary bypass surgery. This study was undertaken to investigate the potential role of Irbesartan in amelioration of myocardial I/R injury induced by ligation of coronary artery (LAD) in a rat model. We are pretreated the animals with Irbesartan 3mg/kg i.p. 30 minutes before ligation of LAD. At the end of experiment (2 h of reperfusion), blood samples were collected from the heart for measurement of plasma level of cardiac troponin I (cTn-I). Compared with the sham group, levels of myocardial TNF-α, IL-1β, IL-6, MCP-1, MIP-1 alpha, and plasma cTn-I were increased (P<0.05). Histologically, all rats in control group showed significant cardiac injury after I-R. Furthermore, rats in control group showed significant apoptosis. Irbesartan significantly counteract the increased in myocardium level of TNF-α, IL-1B, IL-6, MCP-1, MIP-1 alpha, plasma cTn-I and apoptotosis (P<0.05). Histological analysis revealed that Irbesartan markedly reduced the severity of heart injury in the rats underwent LAD ligation procedure. We concluded that Irbesartan may ameliorate myocardial I/R injury in rats via interfering with inflammatory reactions and apoptosis which induced by I/R injury.
Keywords: Ischemia-Reperfusion; LAD; Irbesartan; Cytokines; Apoptosis
References
1. Dorweiler B, Pruefer D, Andrasi TB, Maksan SM, Schmiedt W, Neufang A, et al. Ischemia-Reperfusion Injury. Eur J Trauma and Emerg Surg 2007; 33:600-12. [Abstarct/Full-Text]
2. Anselmi A, Abbate A, Girola F, Nasso G, Biondi-Zoccai GG, Possati G, et al . Myocardial ischemia, stunning, inflammation, and apoptosis during cardiac surgery: a review of evidence. Eur J Cardiothorac Surg 2004; 25: 304-311. [PubMed]
3. Jordan JE, Zhao ZQ, Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res 1999; 43(4):860-78. [PubMed]
4. Eltzschig HK, Collard CD. Vascular ischaemia and reperfusion injury. Br Med Bull 2004; 70:71-86. [PubMed]
5. Lutz J, Thurmel K, Heemann U. Ant-inflammatory treatment strategies for ischemia/reperfusion injury in transplantation. J Inflamm (Lond) 2010; 7:27 [PubMed]
6. Zhao ZQ, Nakamura M, Wang NP, Wilcox JN, Shearer S, Ronson RS, et al. Reperfusion induces myocardial apoptotic cell death. Cardiovasc Res 2000; 45(3):651-60. [PubMed] 7. Kaufmann SH, Hengartner MO. Programmed cell death: alive and well in the new millennium. Trends Cell Biol 2001;11(12):526-34. [PubMed]
8. Nagata S. Apoptotic DNA fragmentation. Exp Cell Res 2000; 256(1):12-8. [PubMed]
9. Dworakowski R, Anilkumar N, Zhang M, Shah AM. Redox signaling involving NADPH oxidase-derived reactive oxygen species. Biochem Soc Trans 2006; 34:960–4. [PubMed]
10. Leri A, Liu Y, Li B, Fiordaliso F, Malhotra A, Latini R, et al. Up-regulation of AT(1) and AT(2) receptors in postinfarcted hypertrophied myocytes and stretch-mediated apoptotic cell death. Am J Pathol 2000; 156(5):1663-72. [PubMed]
11. Nako H, Kataoka K, Koibuchi N, Dong YF, Toyama K, Yamamoto E, Yasuda O, Ichijo H, Ogawa H, Kim-Mitsuyama S. Novel mechanism of angiotensin II-induced cardiac injury in hypertensive rats: the critical role of ASK1 and VEGF. Hypertens Res 2012; 35(2):194-200. [PubMed]
12. Wu Y, Yin X, Wijaya C, Huang MH, McConnell BK. Acute myocardial infarction in rats. J Vis Exp 2011;16(48): 2464. [PubMed]
13. Wiedemann D, Schneeberger S, Friedl P, Zacharowski K, Wick N, Boesch F, et al. The fibrin-derived peptide-B beta (15-42) significantly attenuates ischemia-reperfusion injury in a cardiac transplant model. Transplantation 2010; 89(7):824-9. [PubMed]
14. Ding JW, Tong XH, Yang J, Liu ZQ, Zhang Y, Yang J, Li S, Li L. Activated protein C protects myocardium via activation of anti-apoptotic pathways of survival in ischemia-reperfused rat heart. J Korean Med Sci 2010; 25(11):1609-15. [PubMed]
15. Wayman NS, Ellis BL, Thiemermann C. Simvastatin reduces infarct size in a model of acute myocardial ischemia and reperfusion in the rat. Medical Science Monitor 2003; 9(5):BR155–159. [PubMed]
16. Zingarelli B, Salzman AL, Szabo C. Genetic disruption of poly (ADP-Ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ. Res 1998; 83: 85–94. [PubMed]
17. Huang Z, Jansson L, Sjöholm A. Vasoactive drugs enhance pancreatic islet blood flow, augment insulin secretion and improve glucose tolerance in female rats. Clin Sci (Lond) 2007; 112(1):69-76. [PubMed]
18. Whaley-Connell A, Nistala R, Habibi J, Hayden MR, Schneider RI, et al. Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am J Physiol Renal Physiol 2010; 298(3):F655-61. [PubMed]
19. Preckel B, Schlack W, Gonzàlez M, Obal D, Barthel H, Thämer V. Influence of the angiotensin II AT1 receptor antagonist Irbesartan on ischemia/reperfusion injury in the dog heart. Basic Res Cardiol 2000; 95(5):404-1. [PubMed]
20. Austin EW, Yousif NG, Ao L, Cleveland JC, Fullerton DA, Meng X. Ghrelin reduces myocardial injury following global ischemia and reperfusion via suppression of myocardial inflammatory response. American journal of BioMedicine 2013; 1(2): 38-48. [Abstract/ Full-Text]
21-Granado M, Fernández N, Monge L, Figueras JC, Carreño-Tarragona G, Amor S, García-Villalón AL. Effects of coronary ischemia-reperfusion in a rat model of early over nutrition. Role of angiotensin receptors. PLoS One 2013;8(2):e54984. [PubMed]
22. Tuma RF, Steffens S. Targeting the endocannabinod system to limit myocardial and cerebral ischemic and reperfusion injury. Curr Pharm Biotechnol 2012; 13(1):46-58. [PubMed]
23. Steffens S, Montecucco F, Mach F. The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost 2009; 102(2):240-7. [PubMed]
24. Berthonneche C, Sulpice T, Tanguy S, O’Connor S, Herbert JM, Janiak P, et al. AT1 receptor blockade prevents cardiac dysfunction after myocardial infarction in rats. Cardiovasc Drugs Ther 2005;19 (4):251-9. [PubMed]
25. Sola S, Mir MQ, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S, et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005; 111(3):343-8. [PubMed]
26. Jin HY Song B, Oudit GY, Davidge ST, Yu HM, Jiang YY, et al. ACE2 deficiency enhances angiotensin II-mediated aortic profilin-1 expression, inflammation and peroxynitrite production. PLoS One 2012; 7(6):e38502. [PubMed]
27. Tsukuda K, Mogi M, Iwanami J, Min LJ, Jing F, Oshima K, et al. Irbesartan attenuates ischemic brain damage by inhibition of MCP-1/CCR2 signaling pathway beyond AT₁ receptor blockade. Biochem Biophys Res Commun 2011; 409(2):275-9. [PubMed]
28. Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002; 40(4):521-7. [PubMed]
29. Tsao PS, Wang B, Buitrago R, Shyy JY, Cooke JP. Nitric oxide regulates monocyte chemotactic protein-1. Circulation 1997; 96(3):934-40. [PubMed]
30. Di Filippo Clara, Lampa Enrico ,Martella Rafaelle et al. Effect of Irbesartan on the myocardial ischemia/reperfusion injury in ZDF rats with metabolic syndrome. FASEB J 2000; 1867-69. [Abstract/Full-Text]
3. Jordan JE, Zhao ZQ, Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res 1999; 43(4):860-78. [PubMed]
4. Eltzschig HK, Collard CD. Vascular ischaemia and reperfusion injury. Br Med Bull 2004; 70:71-86. [PubMed]
5. Lutz J, Thurmel K, Heemann U. Ant-inflammatory treatment strategies for ischemia/reperfusion injury in transplantation. J Inflamm (Lond) 2010; 7:27 [PubMed]
6. Zhao ZQ, Nakamura M, Wang NP, Wilcox JN, Shearer S, Ronson RS, et al. Reperfusion induces myocardial apoptotic cell death. Cardiovasc Res 2000; 45(3):651-60. [PubMed] 7. Kaufmann SH, Hengartner MO. Programmed cell death: alive and well in the new millennium. Trends Cell Biol 2001;11(12):526-34. [PubMed]
8. Nagata S. Apoptotic DNA fragmentation. Exp Cell Res 2000; 256(1):12-8. [PubMed]
9. Dworakowski R, Anilkumar N, Zhang M, Shah AM. Redox signaling involving NADPH oxidase-derived reactive oxygen species. Biochem Soc Trans 2006; 34:960–4. [PubMed]
10. Leri A, Liu Y, Li B, Fiordaliso F, Malhotra A, Latini R, et al. Up-regulation of AT(1) and AT(2) receptors in postinfarcted hypertrophied myocytes and stretch-mediated apoptotic cell death. Am J Pathol 2000; 156(5):1663-72. [PubMed]
11. Nako H, Kataoka K, Koibuchi N, Dong YF, Toyama K, Yamamoto E, Yasuda O, Ichijo H, Ogawa H, Kim-Mitsuyama S. Novel mechanism of angiotensin II-induced cardiac injury in hypertensive rats: the critical role of ASK1 and VEGF. Hypertens Res 2012; 35(2):194-200. [PubMed]
12. Wu Y, Yin X, Wijaya C, Huang MH, McConnell BK. Acute myocardial infarction in rats. J Vis Exp 2011;16(48): 2464. [PubMed]
13. Wiedemann D, Schneeberger S, Friedl P, Zacharowski K, Wick N, Boesch F, et al. The fibrin-derived peptide-B beta (15-42) significantly attenuates ischemia-reperfusion injury in a cardiac transplant model. Transplantation 2010; 89(7):824-9. [PubMed]
14. Ding JW, Tong XH, Yang J, Liu ZQ, Zhang Y, Yang J, Li S, Li L. Activated protein C protects myocardium via activation of anti-apoptotic pathways of survival in ischemia-reperfused rat heart. J Korean Med Sci 2010; 25(11):1609-15. [PubMed]
15. Wayman NS, Ellis BL, Thiemermann C. Simvastatin reduces infarct size in a model of acute myocardial ischemia and reperfusion in the rat. Medical Science Monitor 2003; 9(5):BR155–159. [PubMed]
16. Zingarelli B, Salzman AL, Szabo C. Genetic disruption of poly (ADP-Ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ. Res 1998; 83: 85–94. [PubMed]
17. Huang Z, Jansson L, Sjöholm A. Vasoactive drugs enhance pancreatic islet blood flow, augment insulin secretion and improve glucose tolerance in female rats. Clin Sci (Lond) 2007; 112(1):69-76. [PubMed]
18. Whaley-Connell A, Nistala R, Habibi J, Hayden MR, Schneider RI, et al. Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am J Physiol Renal Physiol 2010; 298(3):F655-61. [PubMed]
19. Preckel B, Schlack W, Gonzàlez M, Obal D, Barthel H, Thämer V. Influence of the angiotensin II AT1 receptor antagonist Irbesartan on ischemia/reperfusion injury in the dog heart. Basic Res Cardiol 2000; 95(5):404-1. [PubMed]
20. Austin EW, Yousif NG, Ao L, Cleveland JC, Fullerton DA, Meng X. Ghrelin reduces myocardial injury following global ischemia and reperfusion via suppression of myocardial inflammatory response. American journal of BioMedicine 2013; 1(2): 38-48. [Abstract/ Full-Text]
21-Granado M, Fernández N, Monge L, Figueras JC, Carreño-Tarragona G, Amor S, García-Villalón AL. Effects of coronary ischemia-reperfusion in a rat model of early over nutrition. Role of angiotensin receptors. PLoS One 2013;8(2):e54984. [PubMed]
22. Tuma RF, Steffens S. Targeting the endocannabinod system to limit myocardial and cerebral ischemic and reperfusion injury. Curr Pharm Biotechnol 2012; 13(1):46-58. [PubMed]
23. Steffens S, Montecucco F, Mach F. The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost 2009; 102(2):240-7. [PubMed]
24. Berthonneche C, Sulpice T, Tanguy S, O’Connor S, Herbert JM, Janiak P, et al. AT1 receptor blockade prevents cardiac dysfunction after myocardial infarction in rats. Cardiovasc Drugs Ther 2005;19 (4):251-9. [PubMed]
25. Sola S, Mir MQ, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S, et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005; 111(3):343-8. [PubMed]
26. Jin HY Song B, Oudit GY, Davidge ST, Yu HM, Jiang YY, et al. ACE2 deficiency enhances angiotensin II-mediated aortic profilin-1 expression, inflammation and peroxynitrite production. PLoS One 2012; 7(6):e38502. [PubMed]
27. Tsukuda K, Mogi M, Iwanami J, Min LJ, Jing F, Oshima K, et al. Irbesartan attenuates ischemic brain damage by inhibition of MCP-1/CCR2 signaling pathway beyond AT₁ receptor blockade. Biochem Biophys Res Commun 2011; 409(2):275-9. [PubMed]
28. Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension 2002; 40(4):521-7. [PubMed]
29. Tsao PS, Wang B, Buitrago R, Shyy JY, Cooke JP. Nitric oxide regulates monocyte chemotactic protein-1. Circulation 1997; 96(3):934-40. [PubMed]
30. Di Filippo Clara, Lampa Enrico ,Martella Rafaelle et al. Effect of Irbesartan on the myocardial ischemia/reperfusion injury in ZDF rats with metabolic syndrome. FASEB J 2000; 1867-69. [Abstract/Full-Text]
31. Goette A, Bukowska A, Dobrev D, Pfeiffenberger J, Morawietz H, Strugala D, et al . Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles. Eur Heart J 2009; 30:1411-1420. [PubMed]
32. Ruiz E, Redondo S, Padilla E, Gordillo-Moscoso A, Salaices M, Balfagón G, et al. Importance of intracellular angiotensin II in vascular smooth muscle cell apoptosis: inhibition by the angiotensin AT1 receptor antagonist Irbesartan. Eur J Pharmacol 2007; 567(3):231-9. [PubMed]
33. Dalla Libera L, Ravara B, Angelini A, Rossini K, Sandri M, Thiene G, et al. Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker Irbesartan in experimental heart failure. Circulation 2001; 103(17):2195-200. [PubMed]
34. Preckel B, Schlack W, Gonzàlez M, Obal D, Barthel H, Thämer V. Influence of the angiotensin II AT1 receptor antagonist irbesartan on ischemia/reperfusion injury in the dog heart. Basic Res Cardiol 2000; 95(5):404-12. [PubMed]
35. Zhang J, et al. Inhibition of the activity of Rho-kinase reduces cardiomyocyte apoptosis in heart ischemia/reperfusion via suppressing JNK-mediated AIF translocation. Clin Chim Acta 2009; 401: 76-80. [PubMed]
32. Ruiz E, Redondo S, Padilla E, Gordillo-Moscoso A, Salaices M, Balfagón G, et al. Importance of intracellular angiotensin II in vascular smooth muscle cell apoptosis: inhibition by the angiotensin AT1 receptor antagonist Irbesartan. Eur J Pharmacol 2007; 567(3):231-9. [PubMed]
33. Dalla Libera L, Ravara B, Angelini A, Rossini K, Sandri M, Thiene G, et al. Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker Irbesartan in experimental heart failure. Circulation 2001; 103(17):2195-200. [PubMed]
34. Preckel B, Schlack W, Gonzàlez M, Obal D, Barthel H, Thämer V. Influence of the angiotensin II AT1 receptor antagonist irbesartan on ischemia/reperfusion injury in the dog heart. Basic Res Cardiol 2000; 95(5):404-12. [PubMed]
35. Zhang J, et al. Inhibition of the activity of Rho-kinase reduces cardiomyocyte apoptosis in heart ischemia/reperfusion via suppressing JNK-mediated AIF translocation. Clin Chim Acta 2009; 401: 76-80. [PubMed]
